EGFR and cancer: EGFR-mediated MAPK and PI3K pathways are still activated after chemotherapy because the α α-subunit of glycoprotein hormones (CGA) of N-glycosylated glycoprotein hormones binds to EGFR and activates EGFR signaling, promoting the proliferation and development of cancer cells [83].